Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07155226 2026-05-19

MOMENTUM

84 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02942290 2026-05-18

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

129 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05320198 2026-05-13

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloid

150 enrolled

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT06499285 2026-05-13

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Phase 3 Recruiting

225 enrolled

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

NCT07573111 2026-05-13

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Phase 1 Not yet recruiting

12 enrolled

Phase 2 Active not recruiting

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05583552 2026-05-12

IMpress

46 enrolled 21 charts

Phase 1 Enrolling by invitation

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06788509 2026-05-08

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

316 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04953897 2026-04-30

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

18 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04953910 2026-04-30

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

27 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06782373 2026-04-24

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Phase 2 Recruiting

78 enrolled

VEXAS syndrome, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

260 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT05428969 2026-04-23

BEXMAB

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT05607199 2026-04-17

BHARAT-1

27 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Recruiting

80 enrolled

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT02381886 2026-04-13

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

CNSGastrointestinalMyeloidOther hematologic neoplasm

166 enrolled

Astrocytoma, Glioblastoma, Glioma, Leukemia, Myelodysplastic Syndromes, Oligodendroglioma, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT05732103 2026-04-13

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

225 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06146257 2026-04-13

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06656494 2026-04-13

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

266 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05473910 2026-04-08

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

75 enrolled

Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06419634 2026-04-08

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

105 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04227847 2026-04-07

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05263271 2026-04-06

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

58 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04279847 2026-04-01

LIMBER

140 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05933070 2026-03-30

LAUREL

2 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT06563804 2026-03-30

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Phase 1/2 Terminated

13 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05552469 2026-03-27

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

62 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT07107126 2026-03-25

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

24 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1/2 Suspended

366 enrolled

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

NCT05275439 2026-03-18

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

106 enrolled 28 charts

Phase 3 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05316701 2026-03-04

Orca-T

187 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06846606 2026-03-03

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

34 enrolled

125 enrolled 18 charts 1 FDA

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03802695 2026-02-23

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

300 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05787496 2026-01-28

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

28 enrolled 19 charts

Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05665530 2026-01-26

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Phase 1 Completed

86 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05143996 2026-01-16

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

60 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Phase 2/3 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

289 enrolled 35 charts 1 FDA

Myeloid

Myelodysplastic Syndromes, Recurrence

NCT03573310 2025-12-18

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Phase 1 Completed

114 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms

NCT05086315 2025-12-15

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1/2 Terminated

101 enrolled

Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

665 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT04937166 2025-11-10

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

25 enrolled

MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

116 enrolled 36 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Phase 2 Enrolling by invitation

332 enrolled